Patient Characteristics
| Characteristic | VISION-PET-E | VISION-PET-SF | P |
|---|---|---|---|
| n | 272 | 29 | |
| Median age (y) | 72 (range, 66–76) | 73 (range, 65–76) | 0.91 |
| Median PSA (ng/mL) | 116.6 (interquartile range, 28.4–340.0) | 74.0 (interquartile range, 17.5–198.3) | 0.069 |
| Treatment history | |||
| Previous docetaxel | 218 (80.1%) | 25 (86.2%) | 0.62 |
| Second-line chemotherapy | 95 (34.9%) | 8 (27.6%) | 0.54 |
| Androgen receptor signaling inhibitor | 257 (94.5%) | 27 (93.1%) | 0.67 |
| Extent of disease on PSMA PET/CT | |||
| Number of metastases ≥ 20 | 194 (71.3%) | 16 (55.2%) | 0.089 |
| Number of metastases < 20 | 78 (28.7%) | 13 (44.8%) | |
| Sites of disease on PSMA PET/CT | |||
| Node only (N1 or M1a) | 21 (7.7%) | 1 (3.4%) | 0.71 |
| Bone only (M1b) | 60 (22.1%) | 3 (10.3%) | 0.23 |
| Node + bone (M1b and [N1 or M1a]) | 122 (44.9%) | 8 (27.6%) | 0.08 |
| Viscera (any M1c) | 69 (25.4%) | 17 (58.6%) | <0.001 |
| Number of cycles of 177Lu-PSMA received | |||
| 1 | 38 (14.0%) | 5 (17.2%) | 0.065 |
| 2 | 68 (25.0%) | 13 (44.8%) | |
| 3 | 37 (13.6%) | 5 (17.2%) | |
| 4 | 91 (33.5%) | 5 (17.2%) | |
| >4 | 38 (13.9%) | 1 (3.4%) | |
| Median injected activity per cycle (GBq) | 7.4 (interquartile range, 5.7–8.9) | 7.4 (interquartile range, 6.0–8.5) | 0.30 |